Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immix Biopharma, Inc. (IMMX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret key regulatory documents. Immix Biopharma is a Nasdaq-listed clinical-stage biopharmaceutical company developing cell therapies for relapsed/refractory AL amyloidosis and other serious diseases, and its filings offer detailed insight into governance, financing and risk disclosures that complement its clinical news.
Investors can review current reports on Form 8-K where Immix Biopharma describes material events such as private placements of common stock and non-transferable warrants, registered offerings of common stock and pre-funded warrants under a Form S-3 shelf registration statement, and changes to its board of directors. Filings also confirm that the company’s common stock trades on The Nasdaq Stock Market LLC under the symbol IMMX and document matters submitted to stockholders, including director elections and the ratification of its independent registered public accounting firm.
For longer-term analysis, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available via EDGAR) to study Immix Biopharma’s financial statements, risk factors, and detailed descriptions of its lead BCMA-targeted CAR-T program NXC-201 and the NEXICART-2 clinical trial. AI-generated highlights on Stock Titan help explain complex sections, point out important changes from prior periods, and summarize topics such as capital structure, use of proceeds from offerings, and auditor relationships.
In addition, this page surfaces registration statements, prospectus supplements and related consents that underpin Immix Biopharma’s capital-raising activities. Real-time updates from EDGAR combined with AI summaries make it easier to follow how financings, governance decisions and clinical strategy are reflected in the company’s official regulatory record.
Immix Biopharma, Inc. has filed a shelf registration statement that would allow it to offer and sell up to $750,000,000 of various securities over time. The mixed shelf covers common stock, preferred stock, debt securities, warrants and units, which may also be issued upon conversion or exercise of other registered securities.
Specific terms, prices and amounts for each issuance will be set in future prospectus supplements, and sales may occur through underwriters, dealers, agents or direct transactions. The company currently intends to use net proceeds primarily for working capital and general corporate purposes. Its common stock trades on The Nasdaq Capital Market under the symbol IMMX, and there were 52,955,130 shares of common stock outstanding as of January 8, 2026.
Immix Biopharma is a clinical-stage biopharmaceutical company focused on CAR-T cell therapies, led by its NXC-201 program in AL amyloidosis and other serious diseases. It qualifies as an emerging growth company and a smaller reporting company, which allows reduced reporting and disclosure requirements under U.S. securities laws.
Immix Biopharma director Dr. Nancy T. Chang reported an equity award dated 11/21/2025. She received a stock option (right to buy common stock) for 39,643 shares at an exercise price of $4.33 per share, exercisable until 11/21/2035.
The option will vest in 36 equal monthly installments following the grant date, subject to her continued service and a stock option agreement. After the reported transaction, she beneficially owned 421,940 shares of common stock directly and 496,940 shares indirectly through Robinhood II, LP, where she is general manager and may be deemed to beneficially own those securities while disclaiming ownership beyond her pecuniary interest.
Immix Biopharma, Inc. (IMMX) filed a current report to update the audit firm consents tied to its existing shelf registration. The company obtained new consents dated November 26, 2025 from KMJ Corbin & Company LLP, its former independent registered public accounting firm, and Crowe LLP, its current independent registered public accounting firm. These consents allow the firms’ audit reports dated March 29, 2024 and March 24, 2025 on Immix Biopharma’s consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2024 to be incorporated by reference into the company’s effective Form S-3 registration statement (No. 333-290725) and referenced under the “Experts” section of the related prospectus. The filing does not announce new operating results or business transactions and is primarily an administrative update supporting ongoing use of the existing registration statement.
Immix Biopharma reported third-quarter 2025 results, highlighting continued R&D investment and financing activity alongside a going concern warning. The company posted a net loss of $7,585,692 for Q3 and $18,750,783 for the nine months ended September 30, 2025. Operating expenses were $7,662,509 in Q3, driven by R&D $4,584,131 and G&A $3,078,378.
Liquidity remained constrained with cash and cash equivalents of $15,947,308 at quarter-end and operating cash use of $12,900,697 year-to-date. Management stated there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months.
To fund operations, Immix raised capital via a private placement of 3,915,604 shares and 2,936,709 warrants at a combined price of $2.37, yielding ~$9.3 million gross, and through an ATM program that delivered net proceeds of $2,573,375 for the nine months. The CIRM grant award totals $8 million, with ~$4.6 million received to date and ~$3.4 million remaining subject to milestones. Shares outstanding were 33,577,873 as of November 5, 2025.
Immix Biopharma, Inc. (IMMX) filed a shelf registration on Form S-3 that includes a prospectus outline and an exhibit and security-holder table showing current beneficial holders and share counts as of
The filing references incorporated reports (annual and quarterly reports and proxies) and multiple exhibits and signatures by officers and directors dated
Immix Biopharma insider purchase by CEO/Chairman — This Form 4 shows that Ilya M. Rachman, who is identified as a director and as the CEO and Chairman of Immix Biopharma, Inc. (IMMX), purchased 2,500 shares of the company on 09/17/2025 at a volume-weighted average price of $2.02 per share. After the purchase, the filing reports that Mr. Rachman beneficially owned 1,140,937 shares. The filing includes an explanation that the $2.02 VWAP reflects purchases executed at prices ranging from $2.01 to $2.02 and offers to provide transaction-level detail on request. The form is signed by the reporting person on 09/17/2025.
Immix Biopharma insider purchase: Gabriel Morris, reporting as a Director and CFO, purchased 2,600 shares of Immix Biopharma, Inc. (IMMX) on 09/16/2025 at a price of $1.97 per share. After the transaction he reports 290,659 shares directly beneficially owned and additional indirect holdings of 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures/AVILP, with footnotes clarifying his managerial roles and disclaimer of beneficial ownership except for pecuniary interest. The Form 4 is signed by Gabriel Morris on 09/17/2025.
Dr. Nancy T. Chang filed an initial Form 3 reporting ownership in Immix Biopharma, Inc. (IMMX) related to a 09/08/2025 event. She is identified as a director and the general manager of Robinhood II, LP. The filing shows 421,940 shares of common stock held directly and 496,940 shares held indirectly by Robinhood II, LP. The report also discloses two non-transferable warrants exercisable on 09/08/2025 and expiring 09/05/2035, each covering 316,455 underlying common shares with a $2 exercise price, listed as one direct and one indirect position. The filer states she may be deemed to beneficially own securities held by Robinhood II, LP but disclaims ownership except to the extent of pecuniary interest. The Form is signed on 09/17/2025.
Immix Biopharma, Inc. filed an 8-K disclosing that on
Immix Biopharma, Inc. reported cash and cash equivalents of $11.6 million at June 30, 2025, down from $17.7 million at year-end, total assets of $15.6 million and total stockholders' equity of $4.65 million. The company recorded a $11.17 million net loss for the six months and operating expenses of $11.4 million over the same period, reflecting continued R&D and G&A spending. Management states it does not have sufficient capital to sustain operations through the next twelve months and discloses substantial doubt about the company’s ability to continue as a going concern.
On the financing and development side, Immix established a $50 million ATM facility and sold 513,935 shares for net proceeds of $1.09 million during the quarter (1,015,347 shares sold for $2.43 million as of August 6, 2025). Clinically, lead candidate NXC-201 has favorable early results: prior cohorts showed overall response rates of 100% (10/10) and 94% (15/16) with complete response rates of 70–75%, and the program holds FDA RMAT and orphan drug designations and an $8 million CIRM grant with $3.6 million received to date.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
